28 February 2017 : Clinical Research
Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus
Noriko Ihana-Sugiyama1ABCDEF, Ritsuko Yamamoto-Honda12ACDEF, Takehiro Sugiyama3CDE, Tetsuro Tsujimoto1D, Masafumi Kakei4CDE, Mitsuhiko Noda5ADE*DOI: 10.12659/MSMBR.902218
Med Sci Monit Basic Res 2017; 23:36-44
Abstract
BACKGROUND: Although the efficacy of combination therapy consisting of basal insulin and oral hypoglycemic agents (OHAs) has been shown, which OHAs are the most efficient remains unclear.
MATERIAL AND METHODS: Five patients with type 2 diabetes were enrolled and treated with insulin degludec and metformin as a basal therapy. The patients were randomized in a cross-over fashion to receive a combination of mitiglinide (10 mg) and voglibose (0.2 mg) (M+V) 3 times daily or linagliptin (5 mg) (L) once daily for 8 weeks. After 8 weeks, 2 kinds of meal tolerance tests were performed as breakfast on 2 consecutive days. The first breakfast contained 460 kcal (carbohydrates, 49.1%; protein, 15.7%; fat, 35.2%), while the second contained 462 kcal (carbohydrates, 37.2%; protein, 19.6%; fat, 43.2%). Self-monitoring blood glucose levels were measured at 0, 30, 60, and 120 min after the meal tests, and the increase in the postprandial area under the curve (AUC)0–120 min was determined. The HbA1c, glycated albumin, and 1,5-anhydroglucitol (AG) levels were measured, and continuous glucose monitoring was performed.
RESULTS: The increase in the postprandial AUC0–120 min was significantly smaller in the M+V group than in the L group after both meals. The 24-h average, 24-h standard deviations, 24-h AUC, and mean amplitude of glycemic excursion (MAGE) were similar for both groups and after both meals. The change in 1,5-AG was higher in the M+V group than in the L group.
CONCLUSIONS: The combination of M+V with basal therapy improved postprandial glucose excursion more effectively than L in T2DM patients.
Keywords: Dipeptidyl Peptidase 4, Hyperglycemia, Incretins
Most Viewed Current Articles
30 Oct 2023 : Original article 4,949
Exploring the Impact of the COVID-19 Pandemic on Academic Burnout Among Nursing College Students in China: ...DOI :10.12659/MSMBR.940997
Med Sci Monit Basic Res 2023; 29:e940997
15 Jun 2022 : Clinical Research 4,730
Evaluation of Apical Leakage After Root Canal Obturation with Glass Ionomer, Resin, and Zinc Oxide Eugenol ...DOI :10.12659/MSMBR.936675
Med Sci Monit Basic Res 2022; 28:e936675
07 Jul 2022 : Laboratory Research 4,705
Cytotoxicity, Apoptosis, Migration Inhibition, and Autophagy-Induced by Crude Ricin from Ricinus communis S...DOI :10.12659/MSMBR.936683
Med Sci Monit Basic Res 2022; 28:e936683
01 Jun 2022 : Laboratory Research 4,696
Comparison of Sealing Abilities Among Zinc Oxide Eugenol Root-Canal Filling Cement, Antibacterial Biocerami...DOI :10.12659/MSMBR.936319
Med Sci Monit Basic Res 2022; 28:e936319